National Cancer Institute, Purchasing Support Contract Section, Executive Plaza South, Rm. 638, 6120 Executive Blvd. Bethesda, Md. 20892-7228

B -- RER TESTING & GENOMIC SEQUENCING SOL NCI-RFQ-50112(NS) DUE 091595 POC Patricia Haun, Purchasing Agent (301) 402-4509. RER testing & Genomic sequencing. The National Cancer Institute (NCI) is soliciting proposals from offerors to extract DNA from tumor tissue, adenoma, normal colonic epithelia, other tissue, or peripheral blood will be provided for testing. Arrangements must be made for the expeditious and secure transfer of material from this source to the testing facility. Pick-up of the sample(s) must occur within 48 hours (Monday-Friday, 0900-1700, excluding holidays) of notification of the contractor via phone or fax from the P.I., nurse-geneticist, or designated research fellow. For the retrospective study, the samples will be supplied in batches of greater than or equal to ten. We currently anticipate providing material from 200-400 patients (or relatives) per year. Multiple tests may be performed on a given sample. The tests to be performed will include the following: 1. Determination of microsatellite instability (RER testing). Sets of primers individually flanking at least five and not more than ten regions of microsatellite DNA will be formulated to amplify the microsatellite regions by polymerase chain reaction. The tumors will be categorized as RER+ or RER-. In the case of equivocal results additional primer sets will be tested until a determination of RER status can be made. The retrospective studies batch analysis turnaround time of 8 weeks would be adequate. The prospective studies turnaround time of 1 week from receipt of the sample would be required. 2. Determination of the nucleotide sequence of MSH2, MLH1, PMS1, and PMS2 will be performed on RER+ tumors. Analysis will be performed on DNA extracted from tumor tissue for determination of the nucleotide sequence of the above- named four genes involved in nucleotide mismatch recognition and repair. The work request requires reproducible rapid turnaround RER testing on tumor and normal tissue performed by a CLIA approved laboratory. Solicitation will be issued o/a August 31, 1995 quotations will be due o/a September 15, 1995. All responsible sources may submit a proposal which may be considered by NCI. No collect calls will be accepted. see # Note 1. (0226)

Loren Data Corp. http://www.ld.com (SYN# 0008 19950815\B-0001.SOL)